HF 158K1
Alternative Names: HF-158K1; HFK-1Latest Information Update: 28 Apr 2025
At a glance
- Originator HighField Biopharmaceuticals
- Class Anthracyclines; Antibodies; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Fab fragments; Immunoconjugates
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Apr 2025 HighField Biopharmaceuticals files an IND application with the NMPA in China for Solid tumours
- 21 Apr 2025 HighField Biopharmaceuticals plans a phase I trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater) in China
- 28 May 2024 Pharmacodynamics data from a preclinical studies in Solid tumors released by HighField Biopharmaceuticals